EDIT Clinical trials Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate Published September 02, 2025 at 11:00 AM (NASDAQ:EDIT) EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates Find similar articles on Candlesense globenewswire